Myriad Genetics, Inc.
320 Wakara Way
Salt Lake City
Utah
84108
United States
Tel: 801-584-3600
Fax: 801-584-3640
Website: http://www.myriad.com/
Email: info@myriad.com
About Myriad Genetics, Inc.
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets.YEAR FOUNDED:
May 1991
LEADERSHIP:
CEO and Founder: Mark Capone
CMO (Medical): Richard Wenstrup
CFO: Bryan Riggsbee
CSO (Scientific): Jerry Lanchbury
JOBS:
Please click here for Myriad Genetics job opportunities.
CLINICAL TRIAL
Please click here for clinical trial information.
PRODUCTS:
All Products
FOLLOW MYRIAD GENETICS:
Tweets by Myriad Genetics
691 articles about Myriad Genetics, Inc.
-
Adam Brufsky, MD, PhD, FACP Named Oncology Scientific Advisor to Myriad Genetics
5/31/2023
Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced it has named Adam Brufsky, MD, PhD, FACP, as Scientific Advisor to its oncology business unit.
-
Myriad Genetics Adds Folate Receptor Alpha to Precise™ Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian Cancer
5/24/2023
Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced the addition of Folate Receptor Alpha to its Precise™ Oncology Solutions portfolio.
-
Myriad Genetics Earns 2023 Great Place to Work Certification™
5/8/2023
Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced it has achieved the Great Place to Work® certification for 2023.
-
Myriad Genetics Reports First Quarter 2023 Financial Results; Achieves 10% Revenue Growth Year-Over-Year, the Second Consecutive Quarter of Double-Digit Year-Over-Year Revenue Growth; Raises Mid-Point of 2023 Revenue Guidance Range
5/3/2023
Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced financial results for its first quarter ended March 31, 2023.
-
Myriad Genetics to Participate in BofA Securities Healthcare Conference
5/2/2023
Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced it will be participating in the upcoming BofA Securities Healthcare Conference in Las Vegas, NV.
-
Myriad Genetics to Release First Quarter Financial Results on May 3, 2023
4/26/2023
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its first quarter earnings conference call on Wednesday May 3, 2023 at 4:30 p.m. ET.
-
Myriad Genetics and Intermountain Precision Genomics Now Offer Solid Tumor Testing in All 50 States with Latest NY State Certification
4/18/2023
Myriad Genetics, Inc., a leader in genetic testing and precision medicine, and Intermountain Precision Genomics, a service of Intermountain Health, are now certified to offer solid tumor testing to patients in all 50 U.S. states after receiving the New York State Clinical Laboratory Permit.
-
Myriad Genetics and SimonMed® Imaging Collaborate to Advance Precision Medicine with New Genetic Risk Assessment Program
4/12/2023
Myriad Genetics, Inc. announced the planned launch of a new hereditary cancer assessment program that combines diagnostic imaging, genetic risk assessment utilizing MyRisk® with RiskScore® and patient education.
-
Myriad Genetics Applauds New Expanded Carrier Screening Practice Guidelines from NSGC
3/1/2023
Myriad Genetics, Inc. announced its support for the first evidence-based expanded carrier screening practice guidelines for reproductive risk assessment published by the National Society of Genetic Counselors in the Journal of Genetic Counseling.
-
Myriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight® Volumes
2/28/2023
Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced financial results for its fourth quarter ended December 31, 2022 and provided its outlook on business performance for 2023.
-
Myriad Genetics to Release Fourth-Quarter Financial Results on Feb. 28, 2023
2/22/2023
Myriad Genetics, Inc. will hold its fourth-quarter earnings conference call on Tuesday, Feb. 28, 2023 at 4:30 p.m. ET.
-
Myriad Genetics to Participate in Upcoming Healthcare Conferences
2/9/2023
Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced management will participate at the upcoming healthcare conferences.
-
Myriad Genetics Highlights 2022 Research Findings that Help Advance More Accessible and Equitable Genetic Testing
2/7/2023
Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, highlighted impactful clinical studies from 2022 that underscore the company’s commitment to making genetic testing more accessible and equitable for all patient populations.
-
Myriad Genetics Applauds New Guidelines Recommending Screening for Chromosomal Abnormalities
1/5/2023
Myriad Genetics, Inc. announced its support for a recent guideline update by the American College of Medical Genetics and Genomics, reaffirming the clinical value of non-invasive prenatal screening for a range of chromosomal abnormalities.
-
Myriad Genetics to Present at 41st Annual J.P. Morgan Healthcare Conference
1/4/2023
Myriad Genetics, Inc. announced Paul J. Diaz, president and chief executive officer, and Dale Muzzey, chief scientific officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, Jan. 9, 2023 at 4:30 p.m. PST/7:30 p.m. EST.
-
Myriad Genetics Hires Five Senior Leaders to Advance Commercial Growth Plans
12/19/2022
Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced the addition of five senior executives to help further strengthen the company’s product roadmap and improve commercial execution.
-
Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model
12/9/2022
Myriad Genetics, Inc., a leader in genetic testing and precision medicine, presented results from a longitudinal study validating RiskScore as a well-calibrated and more accurate predictor of breast cancer risk than a standard-of-care risk assessment alone.
-
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Showcasing Advancements in Breast Cancer Risk Assessment and Treatment
11/29/2022
Myriad Genetics, Inc., (NASDAQ: MYGN) a leader in genetic testing and precision medicine, today announced multiple presentations of new data at the 2022 San Antonio Breast Cancer Symposium (SABCS), including a spotlight discussion on breast cancer risk prediction.
-
Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting
11/14/2022
Myriad Genetics, Inc., a leader in genetic testing and precision medicine, will spotlight efforts to expand access to prenatal and hereditary cancer genetic insights at the 41st Annual National Society of Genetic Counselors meeting, Nov. 16-19 in Nashville, Tenn.
-
Myriad Genetics Announces UroSuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-driven Medical Information
11/10/2022
Myriad Genetics, Inc. today announced the launch of UroSuite, a comprehensive suite of genetic risk assessment tests that cover every stage of prostate cancer care.